Ester Aso

Ester Aso

Auto-generated profile, based on publicly available information

Ester Aso

Pharmacology Unit, Department of Pathology and Experimental Therapeutics, School of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, L'Hospitalet de Llobregat, Spain; Neuropharmacology & Pain Group, Neuroscience Program, Bellvitge Institute for Biomedical Research, L'Hospitalet de Llobregat, Spain

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2014 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
EAEster Aso
Ester Aso
Isidro FerrerIsidro Ferrer
Isidro Ferrer
The limited effectiveness of current therapies against Alzheimer’s disease highlights the need for intensifying research efforts devoted to developing new agents for preventing or retarding the disease process. During the last few years, targeting the endogenous cannabinoid system has emerged as a potential therapeutic approach to treat Alzheimer. The endocannabinoid system is composed by a number of cannabinoid receptors, including the well-characterized CB1 and CB2 receptors, with their endogenous ligands and the enzymes related to the synthesis and degradation of these endocannabinoid compounds. Several findings indicate that the activation of both CB1 and CB2 receptors by natural or synthetic agonists, at non-psychoactive doses, have beneficial effects in Alzheimer experimental models by reducing the harmful A peptide action and tau phosphorylation, as well as by promoting the brain’s intrinsic repair mechanisms. Moreover, endocannabinoid signaling has been demonstrated to modulate numerous concomitant pathological processes, including neuroinflammation, excitotoxicity, mitochondrial dysfunction, and oxidative stress. The present paper summarizes the main experimental studies demonstrating the polyvalent properties of cannabinoid compounds for the treatment of Alzheimer’s disease, which together encourage progress towards a clinical trial.

21 May 2013 in Journal of Alzheimer’s Disease
Verified
Journal Article
Open access
PDF file
EAEster Aso
Ester Aso
SJSalvador Juvés
Salvador Juvés
RMRafael Maldonado
Rafael Maldonado
IFIsidro Ferrer
Isidro Ferrer
The specific CB 2 cannabinoid receptor agonist JWH-133 induced cognitive improvement in double AβPP/PS1 transgenic mice, a genetic model of Alzheimer's disease. This effect was more pronounced when administered at the pre-symptomatic rather than the early symptomatic stage. The cognitive improvement was associated with decreased microglial reactivity and reduced expression of pro-inflammatory cytokines IL-1β, IL-6, TNFα, and IFNγ. In addition, JWH-133 reduced the expression of active p38 and SAPK/JNK, increased the expression of inactive GSK3β, and lowered tau hyperphosphorylation at Thr181 in the vicinity of amyloid-β plaques. Moreover, JWH-133 produced a decrease in the expression of hydroxynonenal adducts, and enhanced the expression of SOD1 and SOD2 around plaques. In contrast, the chronic treatment with JWH-133 failed to modify the amyloid-β production or deposition in cortex and hippocampus. In conclusion, the present study lends support to the idea that stimulation of CB 2 receptors ameliorates several altered parameters in Alzheimer's disease such as impaired memory and learning, neuroinflammation, oxidative stress damage and oxidative stress responses, selected tau kinases, and tau hyperphosphorylation around plaques.

29 November 2007 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
EAEster Aso
Ester Aso
Andres OzaitaAndres Ozaita
Andres Ozaita
EVElsa M. Valdizán
Elsa M. Valdizán
CLCatherine Ledent
Catherine Ledent
ÁPÁngel Pazos
Ángel Pazos
OVOlga Valverde
Olga Valverde
Stress can cause damage and atrophy of neurons in the hippocampus by deregulating the expression of neurotrophic factors that promote neuronal plasticity. The endocannabinoid system represents a physiological substrate involved in neuroprotection at both cellular and emotional levels. The lack of CB1 receptor alters neuronal plasticity and originates an anxiety‐like phenotype in mice. In the present study, CB1 knockout mice exhibited an augmented response to stress revealed by the increased despair behavior and corticosterone levels showed in the tail suspension test and decreased brain derived neurotrophic factor (BDNF) levels in the hippocampus. Interestingly, local administration of BDNF in the hippocampus reversed the increased despair behavior of CB1 knockout mice, confirming the crucial role played by BDNF on the emotional impairment of these mutants. The neurotrophic deficiency seems to be specific for BDNF as no differences were found in the levels of nerve growth factor and NT‐3, two additional neurotrophic factors. Moreover, BDNF impairment is not related to the activity of its specific tyrosine kinase receptor or the activity of the transcription factor cAMP responsive element binding. These results suggest that the lack of CB1 receptor originates an enhanced response to stress and deficiency in neuronal plasticity by decreasing BDNF levels in the hippocampus that lead to impairment in the responses to emotional disturbances.

2 December 2014 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
EAEster Aso
Ester Aso
ASAlex Sánchez-Pla
Alex Sánchez-Pla
EVEsteban Vegas
Esteban Vegas
RMRafael Maldonado
Rafael Maldonado
IFIsidro Ferrer
Isidro Ferrer
Several recent findings suggest that targeting the endogenous cannabinoid system can be considered as a potential therapeutic approach to treat Alzheimer's disease (AD). The present study supports this hypothesis demonstrating that delta-9-tetrahydro

1 October 2013 in Brain
Verified
Journal Article
Open access
PDF file
JSJose V. Sanchez-Mut
Jose V. Sanchez-Mut
EAEster Aso
Ester Aso
NPNicolas PANAYOTIS
Nicolas PANAYOTIS
ILIra Lott
Ira Lott
MDMara Dierssen
Mara Dierssen
MEManel Esteller
Manel Esteller
The central nervous system has a pattern of gene expression that is closely regulated with respect to functional and anatomical regions. DNA methylation is a major regulator of transcriptional activity, and aberrations in the distribution of this epigenetic mark may be involved in many neurological disorders, such as Alzheimer’s disease. Herein, we have analysed 12 distinct mouse brain regions according to their CpG 5’-end gene methylation patterns and observed their unique epigenetic landscapes. The DNA methylomes obtained from the cerebral cortex were used to identify aberrant DNA methylation changes that occurred in two mouse models of Alzheimer’s disease. We were able to translate these findings to patients with Alzheimer’s disease, identifying DNA methylation-associated silencing of three targets genes: thromboxane A2 receptor (TBXA2R), sorbin and SH3 domain containing 3 (SORBS3) and spectrin beta 4 (SPTBN4). These hypermethylation targets indicate that the cyclic AMP response element-binding protein (CREB) activation pathway and the axon initial segment could contribute to the disease.

1 April 2015 in Journal of Neuropathology & Experimental Neurology
Verified
Journal Article
Open access
PDF file
ILIrene López-González
Irene López-González
ASAgatha Schlüter
Agatha Schlüter
EAEster Aso
Ester Aso
PGPaula Garcia-Esparcia
Paula Garcia-Esparcia
BABelen Ansoleaga
Belen Ansoleaga
Isidro FerrerIsidro Ferrer
Isidro Ferrer
To understand neuroinflammation-related gene regulation during normal aging and in sporadic Alzheimer disease (sAD), we performed functional genomics